Skip to main content

Table 1 Frequency of CD4+CD62Low, CD8+CD62Low, DX5+, CD19+cells in spleen and blood: major subsets

From: Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model

Treatment Group Spleens Blood
  CD4+CD62Low (%) CD8+CD62Low (%) DX5+ (%) CD19+ (%) CD4+CD62Low (%) CD8+CD62Low (%) DX5+ (%) CD19+ (%)
pCEP4 17.75 ± 0.92 0.997 ± 0.05 3.39 ± 1.26 44.51 ± 3.40 17.62 ± 2.15 5.93 ± 0.96 15.45 ± 1.19 28.97 ± 3.52
pIL-18 30.05 ± 1.85a 1.995 ± 0.34 1.73 ± 0.08 41.57 ± 1.09 30.58 ± 4.59a 9.88 ± 0.94 18.4 ± 2.91 36.49 ± 5.95
  1. Spleen and blood samples of CT26 tumor-bearing mice treated with pCEP4 or mIL-18 plasmid DNA were harvested 7 days after gene treatment, and cells analyzed by flow cytometry using the corresponding FITC-, PE-, or PE-Cy5-conjugated antibodies and isotype control. Data are presented as means ± SD of 8 mice/group. a P < 0.04, compared with the pCEP4 control-treated group.